Evidence map›Paper›PMID 35600872›Full record

ArticleFrontiers in pharmacology2022

Tibetan Herbal Pain-Relieving Plaster for Chronic Musculoskeletal Pain Among Cancer Survivors: Study Protocol of a Randomized, Double-Blind, Placebo-Controlled Trial.

Mingxiao Yang, Raymond E Baser, Susan Q Li, Yen-Nien Hou, Kamyar Chong, Yi Lily Zhang, Irfan Hoque, Ting Bao, Jun J Mao

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04916249 (Tibetree Pain-Relieving Plaster for Musculoskeletal Pain Among Cancer Survivors), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04916249 phase2active not recruitingnot on this map

Tibetree Pain-Relieving Plaster for Musculoskeletal Pain Among Cancer Survivors

TypeinterventionalSponsorMemorial Sloan Kettering Cancer CenterRan2021 to 2027Enrolled68ConditionsCancer, RemissionArmsTibetree Pain Relieving Plaster, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Mingxiao YangDepartment of Medicine, Integrative Medicine Service, Memorial Sloan Kettering, New York, NY, United States.
Raymond E BaserDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering, New York, NY, United States.
Susan Q LiDepartment of Medicine, Integrative Medicine Service, Memorial Sloan Kettering, New York, NY, United States.
Yen-Nien HouDepartment of Medicine, Integrative Medicine Service, Memorial Sloan Kettering, New York, NY, United States.
Kamyar ChongDepartment of Medicine, Integrative Medicine Service, Memorial Sloan Kettering, New York, NY, United States.
Yi Lily ZhangDepartment of Medicine, Integrative Medicine Service, Memorial Sloan Kettering, New York, NY, United States.
Irfan HoqueInvestigational Drug Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Ting BaoDepartment of Medicine, Integrative Medicine Service, Memorial Sloan Kettering, New York, NY, United States.
Jun J MaoDepartment of Medicine, Integrative Medicine Service, Memorial Sloan Kettering, New York, NY, United States.
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Chronic pain is common and debilitating in cancer survivors. Tibetan herbal pain-relieving plaster is used as an external analgesic to treat musculoskeletal pain in China; however, its safety and efficacy have not been evaluated via clinical trials in cancer survivors. We designed this Phase II randomized, double-blind, placebo-controlled trial (ClinicalTrials.gov Identifier: NCT04916249) to assess the efficacy and safety of the pain-relieving plaster for temporary pain relief among cancer survivors with chronic musculoskeletal pain. Under ethical approval from the Institutional Review Board at the Memorial Sloan Kettering Cancer Center, we will enroll eligible cancer survivors who have a clinical diagnosis of moderate to severe chronic musculoskeletal pain in this study. We use a central randomization system to allocate the eligible participants to either the treatment or the control group in a 1:1 ratio, with stratification by baseline opioid use. We will instruct the participants to apply the herbal patch (Tibetree Pain-Relieving Plaster, Tibet Cheezheng Tibetan Medicine Co. Ltd., Tibet, China) or placebo patch daily at the focal area with worst pain for 14 consecutive days. Study physician, participant, outcome assessor, and biostatistician are blinded to the group allocation. The primary outcome is pain severity measured by the Brief Pain Inventory on Days 2-7. Secondary outcomes include changes in insomnia, anxiety, depression, fatigue, pressure pain threshold, pain medication use, and global impression of change. We will also monitor the adverse events throughout the study period. Statistical analysis will follow the intention-to-treat principle and linear mixed modeling will be used. With rigorous design and implementation, this randomized, placebo-controlled trial will provide the initial evidence on the efficacy and safety of the pain-relieving plaster for pain relief among cancer survivors with chronic musculoskeletal pain.

Indexed as

cancer survivorchronic painefficacypatient reported outcome (PRO)randomized clinical trialsafetystudy designTibetan herbal patch

Identifiers

PMID35600872
PMCPMC9114465
OpenAlexW4225417598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.